Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Tegafur-uracil for HCC Recurrence Prevention
NCT02447679Phase 2Completed
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Aug 2010
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Started Aug 2010; status: completed.
02
Drugs
thalidomide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02447679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447679.